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Summary.-This paper explores the factors involved in assessing the value of a
tumour-marker test in differential diagnosis and patient monitoring. The difficulties
have been grosslyunderestimated, and in the past it has been tacitly assumed that an
association between the tumour-marker level and the presence of malignancy is
sufficient to prove the usefulness ofthe test. Part 1 investigates in depth the principles
of design of a study to evaluate a tumour-marker test, bearing in mind the ultimate
aim of improving the patient's prognosis. The preliminary research carried out on
the tumour marker, the laboratory assay technique itself and the "normal" range of
levels or the use of a proposed critical level, are all reviewed. The clinical side
presents many problems, including the precise definition of the medical situation in
which the addition of a new test may assist, and the estimation of the overall size of
this problem. Some examples from studies are given. The general principle of
evaluating a tumour marker by considering the clinical situation first without, and
then with, a tumour-marker result, is stressed. Part 2 gives some practical advice
on the setting-up, administration and analysis of such studies.
PART 1: THEORETICAL CONSIDERATIONS
THIS PAPER IS CONCERNED with the
problems involved in assessing the value
of a single test for the presence of disease
in certain clinical settings. More particu-
larly, attention is focused on the evalua-
tion of a tumour-marker test in oncology,
though many ofthe problems encountered
here are not specific to this situation, and
may be relevant when considering the
value of any test in any clinical situation.
A test for the presence of disease may be
examined in 3 types ofsetting: population
screening, differential diagnosis, and
monitoring for changes.
Screening differs from differential diag-
nosis and monitoring in that the popula-
tion at large, or more usually some subset
of the population deemed to be at particu-
lar or special risk, is examined by the test.
Those who undergo the test are not
knowingly ill and must be persuaded to
attend for the test or must consent to it
being carried out at the same time as some
other investigations (e.g. cervical smears
taken at Family Planning Clinics). Much
has been written on screening, including
the conditions which should prevail for a
successful screening programme, and
giving, in general terms, the characteris-
tics of a disease which would merit screen-
ing. The problems of implementing a pro-
gramme, persuading those at risk to
attend for the test and of assessing the
success of a programme, have all been
discussed elsewhere. For a comprehensive
review see Cole & Morrison (1978). It is
not the aim of this paper to go over this
ground, but instead to examine scientific-
ally the factors involved in assessing a test
as a help in differential diagnosis, in
monitoring patients who have been treated
for cancer and are being followed up, and
in monitoring during treatment. In the
case of differential diagnosis, the patient
is ill and waiting to be diagnosed and
appropriately treated. Here the problem
is immediate, and confounded by the fact
that, unlike screening, a number of
different tests will be carried out more orH. TATE
less simultaneouisly. In the monitoring
situation a patient has uisually been treated
and purportedly cured of cancer and is
being followed up, usually on an out-
patient basis for a number of years.
Againi, a tumour-marker test is carried out
concurrently with other tests and clinical
examination, and is not considered in
isolation. As in screening, the aim is early
detection ofany recurrence ofthe cancer.
Prclimincary re.search
Suppose Substance X is proposed as a
tumouir marker for a certain class of
carcinoma; should a large-scale study into
its uisefulness be mounted? A certain
amount of work will have already been
done on both the laboratory and the
clinical sides and the results look en-
couraging. The claims being made for the
test must now be examined critically and
more fully. The first results must have
appeared very promising, and provided
the impetus for further research. Work
will have been done on more than one
front at the same time, the laboratory
researchers and clinicians working closely,
with each interested in the others' find-
ings. In order to generate mutual interest
and enthusiasm, neither side will have
been "blind" to the results of the other.
Becauise of this, the data examined in the
early stages are likely to be highly
selected, and it must be borne in mind that
they may not be representative.
The patients themselves will have been
selected. On the very basic level it may
occur solely in terms of the geographical
area served by the centre carrying out
this research. However, as is more likely,
if a centre is known for its special interest
in a certain disease or class of diseases,
other factors will be involved:
-certain patients may request referral to
the centre they know to be interested in
the disease they may have;
referral patterns will come about via
GPs, and will relate to the GP's special
interests, contacts and also to geographical
area; and
older, less fit patients may find travel-
ling a longer distance difficult for them-
selves or their relatives, and so may be
referred to the most convenient hospital.
The result could be that quite a different
patient population may attend a certain
specialist hospital doing this research
from the patient population attending a
general hospital 5 miles away.
Once referred to the specialist centre,
patients may be selected to be partici-
pants in a particular study on other
criteria. The following factors are im-
portant:
the presence of particularly distressing
symptoms;
the patient's general compliance; and
-the overall pressure for hospital facili-
ties at that particular time.
Further, the tests and examinations
carried out on patients in a research study
may differ considerably from those car-
ried out on other patients. A centre with a
special interest in a certain disease may
have developed a whole range of addi-
tional tests, besides the tumour marker,
which will be carried out on patients there.
Specialist scanning procedures may be
available at this centre and not at others.
In general, any deviation from the usual
procedure is likely to take the form of the
clinician "looking harder" at patients
involved in a research project. If there is
something to be found, by "looking
harder", the clinician is more likely to find
it. If he finds that a particular patient has
what is agreed to be a very high level of a
tumour marker in his plasma, he may look
even harder and longer at that patient.
In this section I have outlined difficul-
ties which may be inherent and uinavoid-
able at the beginning of this type of
research. It is essential that these be borne
in mind when considering the value of
these data as justification for setting up a
more rigorous study into the usefulness of
a tumour marker. A new study should not
be a continuation of the initial work.
Briefly, it should involve an objective
examination of the clinical situation for
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which the test is proposed (without know-
ledge of the test result), and then an
evaluation of the gain to be made by
adding the test to the other procedures,
together with some estimate of the cost of
carrying out the test, i.e. some sort of
cost/benefit analysis of the test. This is
dealt with in more detail in the second part
of this paper.
The assay
Any study ofthis nature is going to have
to contend with many difficulties on the
clinical front, and for this reason it is
strongly advisable that the laboratory side
be as straightforward as possible. Much of
the groundwork for this can be carried out
independently and in advance of a major
clinical study. The assay technique should
be well developed, and stable standard
preparation or other method to ensure
stability of results over time must exist.
Reagents should be standard and easily
available. The body fluids to be tested,
and the method of obtaining the sample,
should be established.
Sources of variability in assay results
should be investigated in depth. The
reproducibility of results on the same
sample can be easily examined using
well designed experiments, to establish
the degree and sources of within-
laboratory variability. If the assay tech-
nique has been developed and is being per-
formed at more than one laboratory there
will be a need to examine variability
between laboratories, by setting up a
collaborative study. This would be similar
to those adopted by laboratories to estab-
lish a new standard of an important bio-
logical preparation (WHO, 1978). It is
common in such studies to find that
different laboratories using the same
technique find very different levels of a
substance in the same sample. This is
important if some national "normal"
level of a substance is being proposed. For
example, the 3 laboratories cooperating
in the MRC CEA study of colo-rectal
cancer separately quoted their levels
indicative of carcinoma as being values
over 10, 20 and 40 ng/ml, though all were
using the same technique, a double-
antibody radioimmunoassay system.
The cost of a single test in the labora-
tory should be estimated, and the time
taken before the results are known should
be noted.
Tumour-marker levels
The information concerning the levels
of the tumour marker in normal and other
groups of people should be reviewed. The
tumour marker may not be present in
people without a tumour, or may be pre-
sent at levels below the threshold of
detection (the two being indistinguishable
in practice). If the assay technique were
improved, leading to a decrease in the
detection threshold, the levels in the non-
carcinoma population would become
apparent. This is in fact what happened
after CEA was first discovered by Gold &
Freedman in the early 1960s (Gold &
Freedman, 1965; Martin & Martin, 1970).
Assuming the levels in the normal
population to be above the bounds of
detection, it is always necessary to remem-
ber that these data are collected from
people assumed to be normal by default,
rather than showing a negative result to
each of the barrage of tests. Ethical con-
siderations may preclude investigation of
other than self-selected groups. It is
worthwhile, however, devoting consider-
able effort at an early stage by advertising
widely for volunteers, and obtaining the
best possible background information.
Any estimation of a normal upper limit
should be based on a sample of adequate
size for this purpose. It is usual to take
the 95th percentile of the distribution of
values as an upper limit. In the analysis
of data from a clinical study it may not
always be meaningful to use this upper
limit at a critical value. (This point is
dealt with in more detail in Part 2.) Any
hitherto unsuspected sources ofvariability
in tumour-marker levels, such as differ-
ences between males and females, should
be apparent. The variabilityofthe tumour-
marker level over time in the same
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norinal individual is also important and
should be investigated. It is essential to
know whether the range of values for a
normal individual is more or less constant,
or ifsome individuals have a narrow range
and some have a wide range of values.
The levels of the tumour marker in
patients with a certain carcinoma is of
prime importanice, and this information is
available. Again, for the reasons discussed
above, it must be borne in mind that the
carcinoma patients for whom the level of
tumour marker is known may not be
representative ofthose carcinoma patients
in general.
Although an association between the
presence of disease and the tumour-
marker level is essential, stuch an asso-
ciation does not guarantee that the
tumour marker merits further study. It
mnay not offer any further information
than already obtained from conventional
examinations and tests. A difference
betw\Aeen the mea3ns of the distributions of
tumour-marker level in carcinoma patients
and others, even ifit is statistically signifi-
cant, may not be useful if there is con-
siderable overlap of the (listributions.
Fig. 1 illustrates this.
This was fouind to be the case when the
(listribuition ofCEA in urine was examined
in patients with and without carcinoma.
T'he important factor is always the use to
which any difference may be put, rather




1'i. 1. I)i8stributioiis of tumour marker
levels in a sample free from tu1moUr (------
imneamm 1) an(il xNitli tumotur ( mean 2).
Black area: ov0rlap of distributtions.
(Clinical situation
It is necessary to examine in detail the
clinical situation for which the use of the
tumour marker is proposed; as, for ex-
ample, a diagnostic aid, or in patient
monitoring.
Diaynosis
The diagnostic problem must be care-
fully assessed. It should be shown that a
diagnostic problem actually exists, and
that this is potentially solvable by a
tumour-marker test. This is not at all a
straightforward situation, as by definition
these patients must be "patients suspected
of suffering from cancer". The reasons for
the suspicions will vary. Immediately one
is in the difficult area of differential diag-
nosis, involving the quantification of the
likelihood that a certain patient is, in the
clinician's mind, suffering from one of
several possible diseases.
However, at the stage wheni the setting-
lip of a study into the use of a tumour
marker in differential diagnosis is under
consideration, there must be some con-
sensus of opinion oni the definition of
patients, and it mtust be shown that there
is some diffiulty in confirming the actual
diagnosis. The MRC set up 2 studies into
the use of CEA as a diagnostic aid: one
was for patients presenting with haemat-
liria, and the other was for patients pre-
senting with symptoms of )ancreatic
disease. The haematuria patients were
easy to define, but in fact there did not
appear to be a diagnostic problem: 227
patients were enitered into the stuidy and
for 225 a firm diagnosis was made at the
first hospital visit without the aid of a
CEA test. The patients entered into the
pancreatic study were more difficult to
define, and there did appear to be a
diagnostic problem (i.e. distinguishing
between patients with carcinoma of the
pancreas and benign disease). For a report
of this study see M.R.C. (1980).
A review of exactly how the diagnostic
problem is solved currently is of value at
this stage. Establishing the diagnosis may
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span some period of titne; the mechanism
by which the diagnosis is made, the tests
carried out, their reliability, cost, contri-
bution to making the diagnosis, and time
to complete are all important, as any new
test is to be evaluated against this back-
ground. This may be information which is
not readily available and will require some
preliminary research. A ttumour-marker
test could fulfill a useful function by re-
placing an expensive or rare piece of
equipment, or a diffiuclt procedure, at a
much cheaper cost, provided it gives
results which can be interpreted in the
same way.
The incidence of the cancer in question,
the proportion of those patients with
diagnostic difficulties and the number of
patients with non-malignant disease for
whom there exists a diagnostic problem
should be assessed. These numbers will be
needed if an objective estimate of the
benefit from the uise of a new test in the
general population is to be made. The
problem may be represented by a simple
Venn diagram (Fig. 2).
The set outtlined with a bold line is the
one which would benefit from an addi-
tional diagnostic test, and it is relevant to
examine the overall size of this, and the
sizes of its two components. In the MRC
study of the itse of CEA as a help in
differential diagnosis in patients with
pancreatic disease, 30 patients had a final
diagnosis of definite carcinoma. Of these
21 were cotnfirmed without difficulty, and
the other 9 were intially suspected of
haviing carcinoma, which was suibsequently
confirmed. Fifty-three patients had a final
diagnosis of pancreatitis or gallstones and
36 were confirmed immediately, without
difficulty. Seven of the remaining 17 were
initially suspected of pancreatic carcin-
onma and 10 of pancreatitis or gallstones.
This information gives an estimate of the
relative sizes ofthe sets in the diagram for
this particular problem, and also suggests
a possible role for the CEA test: to con-
firm or otherwise, the suspicion of carcin-
oma of the pancreas. It is relevant that
no clinician overlooked the possibility of
carcinoma; there was no case which was
not stuspected initially.
The consequences of the diagnosis
should be considered. If cancer is diag-
nosed the following questions should be
asked:
(1) What is the therapy?
(2) Is the treatment successfutl?
(3) What is the morbidity?
(4) What is the prognosis?
(5) Is treatment of this disease anl area
of current research?
A particularly pertinent question in-
volves the consequences of earlier diag-
n1osis; what is the likely impact in terms
of therapy and prognosis? An answer to
this may be speculative, but should be
accompanied by realistic assessment ofthe
likelihood of attaining a successful treat-
ment. One use of a tumour marker may be
to give particular information, such as the
presence of metastases (i.e. help with
'I'TuIour marker possibly lhelpfuil
CARCINOMA TIENTS NON-CAR NOMA PATIENTS
diagnosis diagnosis diagnosis diagnosis
straightforward diffficult difficut straightforward
FiT(. 2. -Venn (diagr'amI illust,rating paltilents foIr 'whom a tumour-marker test inay ai(l (liagiliosis.
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staging). The relationship between the
tumour-marker level and the size, distri-
bution and activity of the tumour is very
important. The tumour burden (i.e. total
number of viable tumour cells) and the
tumour-marker level may not themselves
be related linearly, but some particular
facet of the tumour may raise levels of the
marker. The site of metastases, and their
distribution, number and size in the target
organ may be important. It would be
necessary to investigate these points in
great detail to obtain the maximum infor-
mation from any study which may be set
up.
Monitoriny
In considering the potential use of a
tumour marker in monitoring patients,
similar problems to those outlined above
are encountered, but in some respects they
are inore easily dealt with. The most rele-
vant use would be in patients followed up
after apparently successful ablative treat-
ment of a primary cancer. These patients
therefore are more easily defined. The
disease will have been staged at or around
treatment and information on the prog-
nosis will be available. The tumour may
be likely to recur locally, to metastatize,
or both, according to the natural history
of the disease. A tumour-marker test
would form an additional part of the
routine follow-up examinations and, as
with the diagnostic situation, must be
assessed in this setting. A follow-up pro-
cedure should be agreed, including the
frequency of examination, specification
of the tests to be carried out on each
occasion, and the overall period of the
follow-up. This should fit in with normal
clinical practice. A stable baseline of con-
ventional tests must serve as a back-
ground against which the addition of a
new test can be assessed. The costs and
contributions of the conventional tests
should be estimated. The role of a tumour-
marker test would be to give early warning
of recurrence not otherwise detectable by
routine investigation at that stage. The
potential use ofthis "lead time" should be
examined, again in relation to therapy and
prognosis. The possibility of therapeutic
intervention on the ground of tumour-
marker result alone should be considered,
as a possible future development, should
an initial study establish the test as useful.
Any intervention should take the form of
a randomized controlled trial, unless there
already exists a successful treatment with
negligible or no side effects.
Another possible role for a tumour
marker is in monitoring the effect of treat-
ment. A direct relationship between the
marker level and the tumour response in
the individual patient must be shown, and
this requires some other method ofmeasur-
ing tumour response. The tumour marker
could be used to "confirm" the success of
ablative surgery for the removal of a
primary carcinoma, or to monitor tumour
response to longer-term treatment such as
chemotherapy.
PART 2: SOME PRACTICAL GUIDELINES
This part contains practical advice on
setting up and conducting a study to
assess the usefulness of a tumour marker.
It is not intended to serve as a compre-
hensive guide to any such study, but to
suggest some basic scientific principles to
help with the setting up of a study and
some practical advice on administration.
It is complementary to Part 1.
Design
The major practical difference between
this type of designed prospective study
and the preliminary research on the
tumour marker is that the work of the
clinicians and ofthe laboratory researchers
must now be separated; i.e. the laboratory
workers should not know the clinical
details of the individual patients, and the
clinicians should not know the result of
the tumour-marker test. The "blindness"
is absolutely essential in a study of this
type to ensure that all samples and all
patients are treated in the same way. The
study must be objective, and the situation
in which the laboratory is requested to
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repeat the tumour-marker test because
carcinoma has been detected or, on the
other hand, the clinician carries out repeat
or extra tests on an individual patient
because he knows the tumour-marker
level is very high, must be avoided. The
information on the clinical details and the
laboratory results should be collected at
one central office. It is only by with-
holding the tumour-marker result from the
clinician that an objective estimate of its
value as an additional test can be made.
Unlike a clinical trial, there is no
straightforward statistical criterion that
can be applied to calculate the number of
patients required in a study ofthis nature.
I would suggest that a minimum of 50
patients be included in a diagnostic study,
to be sufficiently out of the range of
"anecdotal evidence", and 200 in a moni-
toring study (following ablative therapy).
This should allow for dividing patients if
necessary, into 2 or 3 different prognostic
groups and for some loss during the
follow-up period. If it is possible to obtain
this number in a reasonable time at one
centre, it would be worth confining the
study to that one centre. This would
involve fewer clinicians and simplify the
agreement on a baseline of tests against
which the new test would be assessed (i.e.
the normal clinical practice for that
centre). The administration of the study
would be easier. However, it has the dis-
advantage that the tumour marker is
being assessed in a single clinical setting.
If, as is more likely, it is not possible to
obtain the required number of patients
from one centre in a reasonably short
time, I would suggest that the number of
centres included be increased to 3 or 4 (at
a maximum). Any more than 4 will render
the study difficult to administer, and
could lead to inconsistencies on the
clinical side.
If one major laboratory is performing
the assay, it is strongly advisable that all
the samples areassayedbythat laboratory,
even though other laboratories, more
geographically convenient for some
centres, may also carry out the test. By
channelling all the samples to one labora-
tory a major potential source ofvariability
in tumour-marker results can be elimin-
ated.
For studies assessing a tumour marker
for use in diagnosis the patients must be
carefully defined. This has been discussed
in detail previously. Consecutive eligible
patients should all be entered into the
study.
For studies as a monitoring aid, patient
definition is more straightforward. Again,
all eligible patients should be included in
the study. The follow-up policy, including
timing of visits, tests to be carried out at
each visit and total length of follow-up,
must be specified in detail. If one centre
sees patients annually, and another sees
them six-monthly, the latter will detect
recurrences earlier. The data to be col-
lected concerning other diseases and treat-
ments during the surveillance period must
be considered. This is particularly relevant
for middle-aged and elderly patients, who
are likely to suffer from other diseases
when followed over a considerable time
period. A patient who has been admitted
to hospital several times for another
reason is likely to have some examination
related to carcinoma as an "extra",
because the history ofcarcinoma is known.
This type of patient will be scrutinized
more closely than one who only attends
for prescribed routine follow-up.
General administration
Forms should be well designed and
contain the complete information for a
particular patient at a given examination
(which may of course include a non-
routine test, and space should be available
on the form for this). There should be
separate forms for the laboratory and
clinical data, with unambiguous labelling
to avoid any unidentified data. As stated
previously, all forms should be sent to one
central office. This may be situated at one
of the centres involved, though it should
be completely separate from the clinicians
dealing with patients there. Additional
staff may be required to deal with the
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extra workload imposed by a centre's
participation in a study. The person
responsible for completing the forms at
each centre should be familiar with the
principles behind the study and under-
stand the information collected. If there
are staff changes, any new person should
be well informed about the study.
The transport of samples from the
centres to the laboratory must be well
organized, with a clear labelling system.
Any major investigation to be set up
should be preceded by a small-scale pilot
study, to ensure the smooth working of
the system, to check that the study's
requirements fit in with the normal clinical
practice, anid note any deviations, and to
estimate patient accruial. Any serious
differences between a hospital's normal
practice and the study's requirements may
require the redesign of part of the study.
A pilot study offers an opportunity to
establish communication channels be-
tween the laboratory, contributing hos-
pitals and the central office. If possible,
the pilot study should rtun straight into
the major investigation, thereby retaining
as much as possible of the initial data.
Analysis
The data-handling, codinig, storage anid
analysis depend very much oni the details
of the individual study, and thierefore canl
be dealt with only briefly here. Unless the
initention is to collect and analyse a great
deal of data on each patient, it is usually
not worth usinig a computer for less than
100 patients a system involving coding
on to cards should suiffice. For more than
100 patients it may be worth setting up a
system for computer storage, with the
facility to add extra follow-up information
on each patient as it becomes available.
For the analysis, some type of cost/
benefit analysis should be carried out. The
total cost of the test should be estimated
and the benefit which may be achieved
investigated. It is not enough to show an
association between level of tumour mar-
ker and the presence ofdisease. The benefit
shouild assess what use the tumour-
marker result could be put to, to augment
what is known of the state of the patient
at a given time, in the knowledge of the
fate of the patient. For example, although
an upper limit for the normal value of the
tumour marker may be accepted, it may
be valuable to experiment with other
values, to obtain a cut-off point which
gives more useful results. Ifa false positive
is much less desirable than a false nega-
tive, one may choose a high critical level.
This may be especially important if thera-
peutic action is to be taken, using chemo-
therapy with undesirable side-effects. If it
is found that a "normal" patient occasion-
ally has a spurious high value of the
tumour marker, it may be useful to con-
sider two consecutive high readings, or
two high readings within a certain time as
an indicator of malignancy. By devising
simple, unambiguous decision rules, and
looking at the outcomes they predict com-
pared with the actual otutcomes, different
ways of using the tumour-marker result
can be assessed. In general, the analysis
involves examining the best use to which
a tumour-marker test result may be put,
and this may be different for different
clinical situations. A more detailed account
of alternative approaches to the analysis
of this type of data, illustrated bv prac-
tical examples, is to form the subject of a
fututre publication.
I)ISCUSS10N
In this paper the problems iinvolved in
assessing tumour markers have been
described in detail. The main conclusions
are that this sort of research must be
carried out well, and that this is difficult.
The feasibility of any study needs careful
consideration and if it is decided to go
ahead, a good deal ofpreliminary research
will be required. The practical difficulties
of carrying out such a study are described.
The analysis depends on the details of the
individual study but in general involves
examining the reward from the best use of
the tumour-marker results.
A recent consensus statement (Br. Med.
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J., 1981) on the use ofCEA for monitoring
patients after surgical removal of colo-
rectal carcinoma states "The regular and
sequential assay ofplasma CEA is the best
presently available non-invasive tech-
nique for post-operative surveillance of
patients to detect disseminated recurrence
of colorectal cancer." This implies that a
CEA test alone is all that is needed for the
surveillance of these patients, and that
there are no false-negative results. It goes
on to say "In a substantial number of
patients CEA values also become signifi-
cantly raised before metastatic disease can
be detected by clinical or other diagnostic
measures." What exactly is meant by the
word "substantial" is not stated and an
account of exactly what other diagnostic
measures were taken is not given. Later,
a statement admits the existence of false
negatives, but again no indication of the
proportion of these is given: "Further-
more, some patients with recurrence or
advanced colorectal cancer may not show
raised plasma CEA value." These vague
and almost contradictory statements are
counterproductive to the general accept-
ance of a new test. It is not proposed that
a new diagnostic test should be used alone,
but in junction with other tests, and this
involves the scientific examination of a
complex medical situation. Any study set
up to assess a tumour marker must be
well designed and executed if it is to give
a meaningful and unambiguous answer.
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